MedPath

Scilex Receives FDA Guidance for SP-103, a Novel Topical Treatment for Chronic Neck Pain

  • Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a high-concentration lidocaine topical system, after a successful end-of-Phase II meeting.
  • SP-103, a triple-strength formulation of ZTlido, targets chronic neck pain associated with muscle spasms, addressing a significant market estimated at $134.5 billion.
  • Market research projects SP-103 could achieve peak sales of $1.2 billion annually within six years post-launch, driven by substantial utilization intent.
  • Scilex is also exploring strategic options, including a potential spin-off or public listing of Scilex Pharmaceuticals Inc., to maximize company value.
Scilex Pharmaceuticals, a subsidiary of Scilex Holding Company, has announced a successful end-of-Phase II meeting with the FDA regarding its investigational drug, SP-103 (lidocaine topical system) 5.4%. This agreement paves the way for a New Drug Application (NDA) submission upon completion of Phase III trials. SP-103 is being developed for the treatment of chronic neck pain associated with muscle spasms.

Addressing Chronic Neck Pain

Chronic neck pain represents a substantial burden, with the U.S. low back and neck pain market estimated to reach $134.5 billion. SP-103, a next-generation, triple-strength formulation of ZTlido, aims to provide a more effective topical treatment option. According to market research by Syneos Health Consulting, SP-103 has the potential to achieve peak sales of $1.2 billion annually within six years of launch.

Clinical and Strategic Implications

Dmitri Lissin, M.D., Chief Medical Officer of Scilex, stated, "We are very pleased with the end of Phase II meeting and received a clear path forward to NDA for our blockbuster product candidate, SP-103... We are looking forward to conducting Phase 3 trials and believe that Scilex is the only company with technology allowing much higher lidocaine concentration than any other topical lidocaine system treatments. Higher concentration of a drug per covered area of skin is important for achieving therapeutic response."
Scilex Holding Company’s Board of Directors is also exploring strategic options to maximize the value of Scilex and its subsidiaries, including a potential spin-off or public listing of Scilex Pharmaceuticals Inc.

Scilex's Existing Portfolio

Scilex currently markets three FDA-approved products:
  • ZTlido® (lidocaine topical system) 1.8%: For the relief of neuropathic pain associated with postherpetic neuralgia. Gross sales have grown by an average of 50% over the past two years. Distribution outside the U.S. is expected to begin in 2025.
  • ELYXYB®: An oral solution for the acute treatment of migraine, with or without aura, in adults. The U.S. oral migraine drug market was estimated at $1.8 billion in 2022. A New Drug Submission has been filed in Canada.
  • Gloperba®: A liquid oral version of colchicine for the prophylaxis of painful gout flares in adults. The gout treatment market is projected to reach $2.0 billion in the U.S. by 2028.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

PolyPid's D-PLEX100 Phase 3 Trial Advances with Positive DSMB Recommendation and $41 Million Financing

PolyPid's SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeries, will continue enrollment to 800 patients.

Scilex Bio's KDS2010 Shows Promise in Phase 2 Trials for Obesity and Alzheimer's

Scilex Bio's KDS2010, a reversible MAO-B inhibitor, is in Phase 2 trials for obesity, with U.S. patient enrollment planned for 2025, targeting metabolism without affecting appetite.

AXS-12 Demonstrates Long-Term Efficacy and Safety in Narcolepsy Phase 3 Trial

Axsome Therapeutics' AXS-12 (reboxetine) significantly reduced cataplexy attacks compared to placebo in the Phase 3 ENCORE trial, meeting its primary endpoint.

Citius Pharma Gains Clarity on Mino-Lok's Regulatory Path After FDA Meeting

Citius Pharmaceuticals reports a productive Type C meeting with the FDA regarding its Mino-Lok program for catheter-related bloodstream infections (CRBSI).

SpyGlass Pharma Completes Enrollment in Phase I/II Glaucoma Drug Delivery Study

SpyGlass Pharma has finished enrolling patients in its Phase I/II clinical trial evaluating its drug delivery platform for glaucoma and ocular hypertension.

FDA Approves Scemblix as First-Line Treatment for CML, Expanding Novartis' Reach

The FDA has approved Scemblix (asciminib) for first-line treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase.

Scilex Gains FDA Clarity on SP-103 Path to NDA for Chronic Neck Pain

Scilex Holding announced a successful end-of-Phase II meeting with the FDA for SP-103, a high-concentration lidocaine formulation targeting chronic neck pain.

Scilex's SP-103 Lidocaine Topical System Receives Positive FDA Feedback for Chronic Neck Pain

Scilex Pharmaceuticals gains FDA agreement on NDA path for SP-103, a triple-strength lidocaine topical system, after a successful Phase II meeting.

Scilex's SP-103 Receives Positive FDA Feedback, Paving Way for Phase III Trials in Chronic Neck Pain

Scilex Pharmaceuticals' SP-103, a triple-strength lidocaine topical system, has received positive feedback from the FDA, clearing the path for Phase III trials.

Scilex Pharmaceuticals Achieves FDA Agreement on NDA Path for SP-103 in Chronic Neck Pain

Scilex Pharmaceuticals secured FDA agreement on the NDA path for SP-103, a lidocaine topical system 5.4%, following a successful end-of-Phase II meeting.

Reference News

[1]
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company ... - Morningstar
morningstar.com · Oct 30, 2024

Scilex Holding Company announces successful Phase II meeting with FDA, leading to agreed path forward for NDA upon Phase...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy